ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ARGX Argen X SE

332.30
-3.20 (-0.95%)
Last Updated: 07:12:22
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Argen X SE ARGX Euronext Ordinary Share
  Price Change Change Percent Stock Price Last Traded
-3.20 -0.95% 332.30 07:12:22
Open Price Low Price High Price Close Price Prev Close
335.00 331.20 336.50 335.50
more quote information »

Recent News

Date Time Source Heading
5/09/202401:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
5/07/202417:30GLOBEargenx announces results of Annual General Meeting of..
5/07/202401:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
5/02/202401:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
4/16/202401:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
3/27/202402:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
3/26/202416:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
3/26/202402:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
3/07/202416:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
2/29/202401:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
2/26/202401:00GLOBEargenx to Present at Upcoming Investor Conferences
2/22/202401:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
2/20/202401:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
1/18/202401:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
1/08/202401:00GLOBEargenx Highlights 2024 Strategic Priorities
1/02/202401:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
12/20/202301:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
11/28/202301:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
11/16/202307:40GLOBEargenx Announces European Commission Approval of..
11/01/202302:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
10/31/202302:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
10/24/202301:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
9/21/202301:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
9/15/202301:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
8/30/202301:00GLOBEargenx to Present at Upcoming Investor Conferences
7/27/202301:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
7/24/202316:30GLOBEargenx announces closing of global offering
7/20/202301:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
7/19/202317:58GLOBEargenx announces full exercise of underwriters’ option to..
7/18/202321:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
7/17/202316:01GLOBEargenx announces launch of proposed global offering
7/17/202301:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
6/30/202309:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
6/20/202318:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
6/20/202301:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
5/31/202301:00GLOBEargenx to Present at Upcoming Investor Conferences

Your Recent History

Delayed Upgrade Clock